Tracer library / [111In]DOTAGA-FAP-2286-ALB
[111In]DOTAGA-FAP-2286-ALB
Also written as [In-111]In-DOTAGA-FAP-2286-ALB
- Radionuclide
- In-111 t½ 4031.6 min
- Modality
- SPECT
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 0
What it is
- Compound class
- FAP-targeting peptide radioligand with DOTAGA chelator and albumin binder
- Target / mechanism
- Fibroblast activation protein (FAP) PMID 40236533
- Clinical application
- Cancer diagnosis and therapy (FAP-expressing tumors) PMID 40236533
- Theranostic pair
- [225Ac]Ac-DOTAGA-FAP-2286-ALB
Published syntheses
No synthesis has been parsed for this agent yet.
Need this precursor?We can point you to suppliers for [111In]DOTAGA-FAP-2286-ALB, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40236533. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40236533: 'We designed DOTAGA-FAP-2286 and DOTAGA-FAP-2286-ALB'. Stage set/updated at stage 23 from PMID 40236533: 'Preclinical Characterization of Novel FAP-2286-Based Radioligand with Albumin Binder for Improved Tumor Retention.'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to SPECT: In-111 agent whose theranostic partner ac225-dotagafap2286alb carries the therapy isotope Ac-225: this is the imaging half of the pair. Linked articles: PMID 40236533.